In certain circumstances, it is necessary to access the epidural space within the spine. For example, medication is often delivered to the epidural space when providing continuous analgesia to a patient. Generally speaking, there are two primary methods used to confirm placement of a needle within the epidural space during needle advancement into the spine: the hanging drop method and the loss-of-resistance method. In practice, most anesthesiologists use the loss-of-resistance method.
In the loss-of-resistance technique, a needle is first inserted into the interspinous ligament or ligamentum flavum and a syringe containing an air bubble in saline is attached to the hub. After compression of the air bubble by increasing pressure using the plunger of the syringe that supports the needle, the needle is carefully advanced until a loss of resistance from the plunger is observed. When that occurs, it is concluded that the tip of the needle is within the epidural space. At that point, a catheter can be inserted into the space.
After accessing what is believed to be the epidural space, a test dose is typically administered to the patient as further confirmation that the tip of the catheter is within the space. Before the test dose is administered, however, the anesthesiologist normally aspirates the site in which the catheter tip is located to see if blood or cerebrospinal fluid (CSF) is collected. If so, this also provides confirmation that the epidural space has been accessed.
When aspiration is performed and fluid is collected, it is not always apparent whether the fluid is saline (used for loss-of-resistance detection), the anesthetic, or CSF. In such cases, it is not clear whether the catheter is in fact within the epidural space. In this scenario, anesthesiologists treat the catheter as if it is within subarachnoid space and administer the test dose beginning in very small quantities. For example, the anesthesiologist may first administer only one tenth of the typical dose and then increase the dose in further one-tenth increments until the target dose is reached. The reason for this is that even small doses of anesthesia can cause significant adverse effects to the patient, such as numbness of legs and loss of motor control, when it is administered in the subarachnoid space.
In view of the difficulty in knowing whether aspirated fluid is CSF or something else, it can be appreciated that it would be desirable to have means for detecting CSF.
The present disclosure may be better understood with reference to the following figures. Matching reference numerals designate corresponding parts throughout the figures, which are not necessarily drawn to scale.
As described above, it would be desirable to have means for detecting cerebrospinal fluid (CSF), for example, when aspirating the epidural space prior to administering anesthesia. Examples of such means are disclosed herein. As described below, a CSF detection method comprises analyzing the fluid that is collected during aspiration of what is believed to be the epidural space. In some embodiments, a CSF detection device is used that includes a test chamber in which the aspirated fluid is received that contains one or more indicators that provide an indication of when the fluid contains CSF. In some embodiments, the indicators comprise one or more chemical indicator elements that change color when the fluid comprises a particular pH and/or a particular substance commonly found in CSF.
In the following disclosure, various specific embodiments are described. It is to be understood that those embodiments are example implementations of the disclosed inventions and that alternative embodiments are possible. Such alternative embodiments include hybrid embodiments that include features from different disclosed embodiments. All such embodiments are intended to fall within the scope of this disclosure.
With reference to
In regard to pH, a chemical indicator element 34 can change color to indicate the pH of the fluid. If the pH is within the pH range of CSF, i.e., 7.28-7.32, the presence of CSF is confirmed and access of the epidural space is presumed. [Are you certain that range of pH encompasses all CSF? I saw online numbers as high as 7.5.] SF normally contains approximately 50-80 mg/dl of glucose. In some embodiments, glucose detection can be based on the enzymatic glucose oxidase/peroxidase (GOD/POD) method. The reaction utilizes the enzyme glucose oxidase to catalyze the formation of gluconic acid and hydrogen peroxide from the oxidation of glucose. In turn, a second enzyme, peroxidase, catalyzes the reaction of hydrogen peroxide with the chromogen tetramethylbenzidine to form a green dye complex. A positive reaction is indicated by a color change from yellow to green. If this occurs, the presence of CSF is confirmed and access of the epidural space is presumed.
CSF normally contains 15 to 45 mg/dl of protein. In some embodiments, the detection of protein is based on the “protein error of pH indicators” (Sörensen, 1909). An example indicator element that can be used in this test is 3′,3″,5′,5″ tetrachlorophenol-3,4,5,6-tetrabromosulfophthalein. A positive reaction is indicated by a color change from yellow to light green/green. If this occurs, the presence of CSF is confirmed and access of the epidural space is presumed.
Referring back to
With further reference to
In operation, anesthesia and/or other medication can be injected into the filter compartment 16 via the inlet 20. This medication can then pass through the filter 32, through the first one-way valve 26, through the catheter port 24, and then into the catheter for delivery to the patient. When fluid is aspirated, a vacuum is applied to the drain 22 to draw fluid from the catheter through the catheter port 24, through the second one-way valve 28, and into the detection compartment 18 in which the fluid contacts the one or more chemical indicator elements 34. If CSF is within the fluid, the one or more chemical indicator elements 34 will change color and the location of the catheter within the epidural space is confirmed.
This application claims priority to co-pending U.S. Provisional Application Ser. No. 63/058,655, filed Jul. 30, 2020, which is hereby incorporated by reference herein in its entirety.
Number | Date | Country | |
---|---|---|---|
63058655 | Jul 2020 | US |